Alpa Laboratories Ltd (NSE: ALPA, BSE: 532878) is an Indore, Madhya Pradesh-based company in the Pharmaceuticals industry. With a market capitalisation of ₹121 Cr, it ranks #3,092 by market cap among the 6,197 Indian listed companies on FinBizNet, and #43 of 63 in Pharmaceuticals. At ₹55.57 (as of 16 Nov 2026), the share price is 39.9% below its 52-week high of ₹92.50 and 20.5% above its 52-week low of ₹46.10. The share price is down 35.7% over one year and down 15.0% over three months.
| Current Price | ₹55.57 |
|---|---|
| Market Cap | ₹121 Cr |
| NSE Symbol | ALPA |
| BSE Code | 532878 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 7.9 |
| Return on Equity | 8.39% |
| Return on Assets | 0.32% |
| 52-Week Range | ₹46.10 – ₹92.50 |
| 1-Year Price Change | -35.7% |
| 3-Month Price Change | -15.0% |
| Beta (1Y) | 0.97 |
| Headquarters | Indore, Madhya Pradesh |
| Website | www.alpalabs.in |
| Revenue | ₹31 Cr |
|---|---|
| Net Profit | ₹-2 Cr |
| Net Margin | -6.0% |
| EPS (Basic) | ₹-0.85 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Alpa Laboratories Ltd reported revenue of ₹31 Cr in Q2 FY27, up 18.0% from ₹26 Cr in Q2 FY26 and up 29.5% from ₹24 Cr in Q1 FY27. It posted a net loss of ₹2 Cr for the quarter, against a net profit of ₹0 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹19 Cr (Q1 FY26) to ₹40 Cr (Q4 FY25). The company reported a net loss in 2 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹31 Cr | −₹2 Cr | −6.0% |
| Q1 FY27 | ₹24 Cr | ₹1 Cr | 4.1% |
| Q4 FY26 | ₹31 Cr | ₹1 Cr | 4.4% |
| Q3 FY26 | ₹29 Cr | ₹2 Cr | 6.5% |
| Q2 FY26 | ₹26 Cr | ₹0 Cr | 0.4% |
| Q1 FY26 | ₹19 Cr | ₹12 Cr | 61.6% |
| Q4 FY25 | ₹40 Cr | −₹2 Cr | −5.3% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 57.19% of Alpa Laboratories Ltd's shares as of Sept 2026, against 57.29% in Sept 2025 (−0.10 percentage points). Delivery averaged 66.8% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Alpa Laboratories Limited engages in the manufacture and sale of drugs and chemicals in India. It provides formulations that address various therapeutic segments. The company was incorporated in 1988 and is based in Indore, India.
1. Drugs and Chemicals-This segment manufactures and markets pharmaceutical formulations under its own brand and for various pharmaceutical companies. It offers various products for human use and veterinary products.
1. Drugs and Chemicals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Alpa Laboratories Ltd | ₹121 Cr | 7.9 | 8.39% | ₹31 Cr | -35.7% |
Listed by market capitalisation. Ratios are shown for context only.
Alpa Laboratories Ltd is trading at ₹55.57, with a market capitalisation of ₹121 Cr.
Alpa Laboratories Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Alpa Laboratories Ltd has a P/E of 7.9 and a return on equity of 8.39%.
Alpa Laboratories Ltd is listed on the NSE under the symbol ALPA and on the BSE under the scrip code 532878.
Alpa Laboratories Ltd's share price is down 35.7% over one year and down 15.0% over three months. Its 52-week range is ₹46.10 to ₹92.50.
In Q2 FY27, Alpa Laboratories Ltd reported revenue of ₹31 Cr and net profit of ₹-2 Cr, with basic EPS of ₹-0.85 (consolidated, parsed from the company's exchange filing).
Alpa Laboratories Ltd reported revenue of ₹31 Cr in Q2 FY27, up 18.0% from ₹26 Cr in Q2 FY26 and up 29.5% from ₹24 Cr in Q1 FY27.
Promoters held 57.19% of Alpa Laboratories Ltd's shares as of Sept 2026, against 57.29% in Sept 2025 (−0.10 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.